GMABGenmabRunning, no new patients
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
Malignant Solid Tumor · Non-Small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC) · Melanoma · Head and Neck Squamous Cell Carcinoma (HNSCC) · Pancreatic Ductal Adenocarcinoma (PDAC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 350 (final count)
- Started
- Sep 17, 2019
- Main results expected
- Dec 30, 2025
- Fully finished
- Jan 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Dose Escalation and Safety Run-in Parts: Number of Participants With Dose-Limiting Toxicities (DLTs)
Measured over: First Cycle (21 days)
Dose Expansion: Objective Response Rate (ORR)
Measured over: Up to approximately 2 years and 4 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04083599 · record last updated 2026-08-04 · checked 2026-11-09 15:47 UTC